{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:46:17Z","timestamp":1790520377437,"version":"4.1.0"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamadermatol.2018.2690","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T23:33:06Z","timestamp":1535671986000},"page":"1208","source":"Crossref","is-referenced-by-count":125,"title":["Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis"],"prefix":"10.1001","volume":"154","author":[{"given":"Alison D.","family":"Treister","sequence":"first","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Kraff-Cooper","sequence":"additional","affiliation":[{"name":"Kraff Eye Institute, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"dbr180017r1","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10086","key":"dbr180017r2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"dbr180017r3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis.","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"dbr180017r4","first-page":"S2213-2198(18)30089-8","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"dbr180017r5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study.","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"dbr180017r6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels?","volume":"178","author":"Thyssen","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"dbr180017r7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels?: reply from the authors.","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"dbr180017r8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis.","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dbr180017r9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti\u2013IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE).","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"dbr180017r10","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells.","volume":"56","author":"Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"dbr180017r11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab.","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edhub.ama-assn.org\/journals\/jamadermatology\/fullarticle\/2697563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:09:08Z","timestamp":1539202148000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.2690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.2690","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}